A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Veverimer in Adults With CKD and Metabolic Acidosis (The REVIVE Study)

Inclusion Criteria: * Written informed consent. * ≥ 18 years old (male/female)). * CKD with eGFR \< 60 mL/min/1.73m²; not expected to need dialysis/ transplant during study. * 2 SBC values 12-21 mmol/L within 6 months pre-screening * During screening: 2 central SBC values 12-21 mmol/L * Willing to maintain stable diet . * Expect to keep oral alkali therapy dose stable. * Women of childbearing potential: negative pregnancy test and agree to abstinence or contraception. Exclusion Criteria: * Any participant deemed by the Investigator to be an inappropriate candidate for physical performance t…